Cease & Desist notice issued to owners of a Colorado-based website, www.pingueculaeyedrops.com which was infringing Ocular Discovery’s US patents by offering dipyridamole-containing eye drops. The infringers have ceased sales of their infringing product and transferred ownership of their domains to Ocular Discovery Ltd.
Fifth patent allowance issued in the United States, toward the use of topical dipyridamole for the treatment of melanocytic nevus, cataracts, and ocular melanoma.
Fourth patent allowance issued in the United States, the for the use of dipyridamole in the following indications: keratitis, corneal abrasions, and corneal ulcers
Patient recruitment complete in India for trial exploring the use and effectiveness of Dipyridamole eye drops for the symptomatic treatment of Pterygium.
Trial completion expected by May 2019
Patent allowance issued in China for the indications of Dry Eye Disease, Sjogren’s Syndrome, Pterygium, Pinguecula, and Corneal Neovascularization
Third patent allowance issued in the United States for the indication of Conjunctivitis
Patent allowance issued in Australia for the indication of Lacrimal and Anterior Eye Segment Disorders
Preclinical experiments support the anti-angiogenic effects of Ocular Discovery’s Dipyridamole drops
Second patent allowance issued in the USA for the treatment of Pterygium, Pinguecula, and Corneal Neovascularization
Medical Device Approval & Free Sale Certificate granted by Israeli Ministry of Health for Ocular Discovery’s Dipyridamole patented dose range eye drop formulation
Ocular Discovery secures $4.4 Million in seed funding led by Norma Investments
Patent allowance granted in Israel for the indication of Lacrimal and Anterior Eye Segment Disorders
Ocular Discovery receives its first patent allowance in the United States for the indications of Lacrimal System Disorders, Dry Eye and Sjogren’s syndrome in the eye